All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

AstraZeneca's durvalumab wins NICE backing for muscle-invasive bladder cancer following Ph3 trial success
Antibody, cancer, monoclonal antibody, bladder cancer, PD-L1 inhibitor, perioperative therapy - Read more

FDA approves Merck & Co.'s Keytruda (pembrolizumab) targeting PD-1 for platinum-resistant ovarian cancer following Ph3 trial
Antibody, cancer, monoclonal antibody, ovarian cancer, PD-1 inhibitor, combination therapy - Read more

THE GOOD
Business Development & Partnerships

Moderna, Mexico sign five-year manufacturing pact for respiratory vaccine supply and technology transfer
Manufacturing agreement, vaccine, technology transfer, pandemic preparedness - Read more

Evogene, Google Cloud expand collaboration to integrate AI agents into ChemPass AI platform
Research collaboration, AI/ML, small molecule, drug discovery - Read more

Insilico Medicine, China Medical System partner on AI-driven CNS, autoimmune drug development for up to $9M per programme
Research collaboration, neurological, autoimmune, AI/ML, milestone payments - Read more

Biocodex, THX Pharma license rare disease programs Batten-1 and TX01, €12M ($14.3M) upfront, €161M ($191.7M) milestones
Licensing deal, rare disease, milestone payments, royalties - Read more

OliX, Key2Brain collaborate on CNS siRNA conjugates using BBB shuttle technology
Research collaboration, neurological, gene therapy, licensing deal - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Nektar Therapeutics reports positive Ph2 maintenance results for rezpegaldesleukin IL-2 agonist in atopic dermatitis
Protein therapy, autoimmune, IL-2 agonist, atopic dermatitis, Treg mechanism - Read more

Kailera Therapeutics and Hengrui advance ribupatide for obesity to Ph3 following positive Ph2 results in China
Small molecule, metabolic, GLP-1/GIP dual agonist, obesity, oral formulation - Read more

Evommune's EVO301 shows 33% improvement in atopic dermatitis Ph2a trial targeting IL-18 pathway
Protein therapy, autoimmune, fusion protein, atopic dermatitis, IL-18 target - Read more

AstraZeneca reports elecoglipron weight-loss pill met Phase 2 endpoints, advancing to Phase 3 trials
Small molecule, obesity, strategic, major transaction - Read more

OrsoBio's TLC-2716 meets Ph2a primary endpoint for severe hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease
Small molecule, metabolic, liver X receptor inverse agonist, hypertriglyceridemia, MASLD - Read more

THE GOOD
Earnings & Finances

AstraZeneca targets $80B revenue by 2030 with 25+ blockbusters amid catalyst-rich clinical pipeline
Monoclonal antibody, oncology, strategic, financial, revenue impact - Read more

Incyte reports Opzelura sales hit $678M, up 33%, as Jakafi faces 2028 generic competition
JAK inhibitor, dermatological, strategic, revenue impact - Read more

THE GOOD
Fundraises

Kainova Therapeutics raises $32M CAD ($23.6M) Series B, accelerating immuno-oncology and inflammation therapies
Immuno-oncology, antibody, small molecule, GPCR-targeting, clinical-stage - Read more

ILiAD Biotechnologies raises $115M Series B, intranasal pertussis vaccine Phase III
Infectious disease, vaccine development, intranasal delivery, clinical-stage - Read more

ArrayPatch raises €1.9M ($2.26M) Seed funding, developing microneedle-based therapeutics for nail fungus
Microneedle platform, dermatology, drug delivery, preclinical - Read more

4Moving raises €12M ($14.3M) funding, developing disease-modifying drugs for osteoarthritis
Clinical-stage, osteoarthritis, disease-modifying drugs, small molecule - Read more

Pandorum Technologies raises $18M Series B, advancing exosome-based regenerative therapies
Regenerative medicine, exosome therapy, ophthalmology, rare disease, tissue engineering - Read more

Cascade Pharmaceuticals raises $72M funding, pursuing MASH, obesity and diabetes drugs
MASH, obesity, diabetes, small molecule, clinical-stage - Read more [Paywall]

THE GOOD
Investments

PharmaEssentia to build $46M manufacturing plant in Puerto Rico for rare blood disease treatment Besremi
Interferon, rare disease, strategic, major transaction, operational - Read more

THE GOOD
Regulatory

FDA accepts Takeda's oveporexton (TAK-861) NDA with priority review for narcolepsy type 1 treatment
Small molecule, neurological, orexin receptor agonist, narcolepsy type 1, first-in-class therapy - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

NIH halts Bayer and Johnson & Johnson's Xarelto (rivaroxaban) Ph3 stroke prevention trial due to safety concerns
Small molecule, cardiovascular, anticoagulant, stroke prevention, combination therapy, rivaroxaban - Read more

AstraZeneca discontinues AZD3427 relaxin-2 analog development after poor Ph2 efficacy in heart failure
Protein therapy, cardiovascular, relaxin-2 analog, heart failure, fusion protein - Read more

THE BAD
Regulatory

FDA issues untitled letters to Novo Nordisk, argenx, Sobi for false or misleading drug advertisements
Small molecule, metabolic disease, regulatory, operational - Read more

FDA warns Hims & Hers' pharmacy over manufacturing violations including pest infestation, patient safety issues
Small molecule, metabolic, operational, manufacturing quality - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here